What happened
Cellromax Science reported consolidated results for FY2025: revenue of US$15.4M (+2.56% year on year), operating profit of US$1.95M (−48.97% year on year) and net income of US$1.85M (−30.16% year on year).
Korean rules require this filing when revenue or profit moves 30% or more from the prior year (15% for large companies). The figures are the company's own and may not be audited yet.
| Revenue | US$15.4M |
|---|---|
| Revenue vs a year earlier | +2.56% |
| Operating profit | US$1.95M |
| Net income | US$1.85M |
| Period | FY2025 (consolidated) |
| Filed | 2026-02-13, Change of 30% or more in revenue or profit/loss structure (15% for large companies) |
| Source | DART rcept 20260213900961 → open original filing |
Source: DART. Information only, not investment advice.